Before taking Hernexeos(Zongertinib)

Key precautions involve monitoring liver function, cardiac health, and lung symptoms.

Warnings and Monitoring

Vital precautions include regular monitoring of liver function tests (ALT, AST, bilirubin) at baseline, every two weeks for the first 12 weeks, and then monthly. Left ventricular ejection fraction (LVEF) should be assessed before initiation and monitored periodically. Patients must be monitored for new or worsening respiratory symptoms indicative of interstitial lung disease. Due to embryo-fetal toxicity, females of reproductive potential must use effective contraception during and for two weeks after treatment. Concomitant use with strong CYP3A inducers should be avoided.